Patients' dissatisfaction with multifocal intraocular lenses managed by exchange with other multifocal lenses of different optical profiles
- PMID: 35227312
 - PMCID: PMC8887122
 - DOI: 10.1186/s40662-022-00280-8
 
Patients' dissatisfaction with multifocal intraocular lenses managed by exchange with other multifocal lenses of different optical profiles
Abstract
Background: The aim of the study was to evaluate the outcomes of dissatisfied patients reporting poor visual quality following implantation of multifocal intraocular lenses (MF-IOLs), managed by IOL exchange with another multifocal optical profile.
Methods: This is a retrospective series of cases. MF-IOL exchange was done in 15 dissatisfied patients (30 eyes) with the perception of poor visual quality for far distance affected by neuroadaptation failure. Patients underwent a bilateral exchange of a MF-IOL with another MF-IOL of a different optical profile. Visual outcomes and complications were analyzed. Questionnaires including Quality of Vision (QoV), Visual Function Index-14 (VF-14) and its Rasch-revised version (VF-8R) and a satisfaction questionnaire were also used for outcome evaluation.
Results: The mean elapsed time from implantation to explantation-reimplantation was 11.8 months. The QoV scores improved significantly across all the three subscales. Visual function improved with a change in VF-14 score from 60.41 ± 24.81 to 90.16 ± 10.91 (P < 0.001). The VF-8R score improved as well. The uncorrected distance visual acuity improved from 0.24 to 0.12 logMAR after exchange (P < 0.001) and corrected distance visual acuity improved from 0.15 to 0.04 logMAR (P < 0.001). Safety and efficacy indexes reached 1.46 and 1.16, respectively. Concerning patients' satisfaction following MF-IOL exchange, 80% of the patients reported they would have the MF-IOL reimplantation procedure again.
Conclusions: Patient dissatisfaction with neuroadaptation failure following MF-IOL implantation can be managed in 80% of our cases by MF-IOL exchange with a different MF-IOL optical profile.
© 2022. The Author(s).
Conflict of interest statement
Jorge L. Alio: Akkolens (C,S); Carl Zeiss Meditec (S,C); CSO (S); Hanita Lenses (C,S); Ophthec (L); Tekia (O); Associate editor of Eye and Vision; C = Consultant/advisor; E = Employee; L = Lecture fees; O = Equity owner; P = Patents/royalty; S = Clinical research grant. Colm McAlinden: Consultancy: Alcon, ClarVista, Ophtec, Acufocus, STAAR Surgical, RxSight, Bausch and Lomb, Perfect lens, Power Vision, Zeiss, Sight Glass Vision, CORD LLC, Ora, targomed GmbH, LensGen, PhysIOL, Ocudyne, Schwind; Travel: Thea, Bayer, Allergan; Editorial board member of Eye and Vision. Jorge L. Alió del Barrio: None. Olena Al-Shymali: None. Mario Canto-Cerdan: None.
References
Grants and funding
LinkOut - more resources
Full Text Sources
